Literature DB >> 24168107

Effect of mushroom diet on pharmacokinetics of gabapentin in healthy Chinese subjects.

Dorothy Su Lin Toh1, Lie Michael George Limenta, Jie Yin Yee, Ling-Zhi Wang, Boon-Cher Goh, Michael Murray, Edmund Jon Deoon Lee.   

Abstract

AIMS: This study evaluated the pharmacokinetics of gabapentin in Chinese subjects who received a diet rich in shiitake mushrooms. Shiitake mushrooms have been shown to contain high amount of ergothioneine. In vitro studies have shown that OCTN1-mediated secretion of gabapentin is trans-stimulated by ergothioneine. This study also investigated the concentrations of ergothioneine in plasma at baseline and following mushroom consumption.
METHODS: Ten healthy male subjects were recruited and received a diet containing no mushrooms (treatment A) or a high mushroom diet (treatment B; after at least a 7 day washout period) 1 day prior to administration of a single oral dose of gabapentin 600 mg.
RESULTS: Ingestion of shiitake mushrooms produced significant increases in plasma ergothioneine concentrations that were sustained for more than 48 h. A statistically significant but modest increase in the renal clearance (CLR ) of gabapentin occurred after intake of the mushroom diet (91.1 ± 25.1 vs. 76.9 ± 20.6 ml min(-1) , P = 0.031). No significant changes in AUC(0,tlast ) of gabapentin were observed (P = 0.726). Creatinine clearance did not correlate with CLR of gabapentin at baseline (treatment A). After ingestion of the mushroom diet, creatinine clearance accounted for 65.3% of the variance in CLR of gabapentin.
CONCLUSIONS: These data suggest that diet-drug pharmacokinetic interactions may occur during co-exposure to gabapentin and mushroom constituents. However, as it does not affect the AUC(0,tlast ) of gabapentin, it may not have clinically important consequences. Shiitake mushrooms can also be used as a source of ergothioneine for future clinical studies.
© 2013 The British Pharmacological Society.

Entities:  

Keywords:  ergothioneine; gabapentin; mushroom; novel human organic cation transporter 1; pharmacokinetics

Mesh:

Substances:

Year:  2014        PMID: 24168107      PMCID: PMC4168387          DOI: 10.1111/bcp.12273

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  14 in total

1.  PEPT1 enhances the uptake of gabapentin via trans-stimulation of b0,+ exchange.

Authors:  Theresa V Nguyen; David E Smith; David Fleisher
Journal:  Pharm Res       Date:  2006-12-28       Impact factor: 4.200

2.  Quantification of L-ergothioneine in human plasma and erythrocytes by liquid chromatography-tandem mass spectrometry.

Authors:  Ling-Zhi Wang; Win-Lwin Thuya; Dorothy Su-Lin Toh; Michael George-Limenta Lie; Jie-Ying Amelia Lau; Li-Ren Kong; Seow-Ching Wan; Kian-Ngiap Chua; Edmund Jon-Deoon Lee; Boon-Cher Goh
Journal:  J Mass Spectrom       Date:  2013-03       Impact factor: 1.982

3.  Effects of age and gender on single-dose pharmacokinetics of gabapentin.

Authors:  R A Boyd; D Türck; R B Abel; A J Sedman; H N Bockbrader
Journal:  Epilepsia       Date:  1999-04       Impact factor: 5.864

4.  Discovery of the ergothioneine transporter.

Authors:  Dirk Gründemann; Stephanie Harlfinger; Stefan Golz; Andreas Geerts; Andreas Lazar; Reinhard Berkels; Norma Jung; Andrea Rubbert; Edgar Schömig
Journal:  Proc Natl Acad Sci U S A       Date:  2005-03-28       Impact factor: 11.205

5.  Determination of gabapentin in human plasma using hydrophilic interaction liquid chromatography with tandem mass spectrometry.

Authors:  Hye Young Ji; Dong Won Jeong; Young Hoon Kim; Hui-Hyun Kim; Yoo-Seok Yoon; Kang Choon Lee; Hye Suk Lee
Journal:  Rapid Commun Mass Spectrom       Date:  2006       Impact factor: 2.419

6.  Studies on ergothioneine. VI. Distribution and fluctuations of ergothioneine in rats.

Authors:  H Kawano; M Otani; K Takeyama; Y Kawai; T Mayumi; T Hama
Journal:  Chem Pharm Bull (Tokyo)       Date:  1982-05       Impact factor: 1.645

7.  A saturable transport mechanism in the intestinal absorption of gabapentin is the underlying cause of the lack of proportionality between increasing dose and drug levels in plasma.

Authors:  B H Stewart; A R Kugler; P R Thompson; H N Bockbrader
Journal:  Pharm Res       Date:  1993-02       Impact factor: 4.200

Review 8.  Gabapentin: pharmacokinetics, efficacy, and safety.

Authors:  A Beydoun; B M Uthman; J C Sackellares
Journal:  Clin Neuropharmacol       Date:  1995-12       Impact factor: 1.592

9.  Functional effects of protein sequence polymorphisms in the organic cation/ergothioneine transporter OCTN1 (SLC22A4).

Authors:  Thomas J Urban; Chen Yang; Leah L Lagpacan; Chaline Brown; Richard A Castro; Travis R Taylor; Conrad C Huang; Douglas Stryke; Susan J Johns; Michiko Kawamoto; Elaine J Carlson; Thomas E Ferrin; Esteban G Burchard; Kathleen M Giacomini
Journal:  Pharmacogenet Genomics       Date:  2007-09       Impact factor: 2.089

10.  Dietary sources and antioxidant effects of ergothioneine.

Authors:  Janine Ey; Edgar Schömig; Dirk Taubert
Journal:  J Agric Food Chem       Date:  2007-07-06       Impact factor: 5.279

View more
  4 in total

1.  Editors' pick 2014.

Authors:  Yoon K Loke; Andrew A Somogyi; Albert Ferro; James M Ritter
Journal:  Br J Clin Pharmacol       Date:  2015-03       Impact factor: 4.335

Review 2.  HDI Highlighter, The First Intelligent Tool to Screen the Literature on Herb-Drug Interactions.

Authors:  Anthony Cnudde; Patrick Watrin; Florence Souard
Journal:  Clin Pharmacokinet       Date:  2022-05-31       Impact factor: 5.577

3.  Development and validation of a rapid liquid chromatography/tandem mass spectrometry method to quantitate gabapentin and buprenorphine in human serum.

Authors:  Sarah J Phillips; Alison Oliveto; Michael J Mancino; Howard P Hendrickson
Journal:  Rapid Commun Mass Spectrom       Date:  2021-07-31       Impact factor: 2.586

4.  Ultra-High-Precision, in-vivo Pharmacokinetic Measurements Highlight the Need for and a Route Toward More Highly Personalized Medicine.

Authors:  Philip A Vieira; Christina B Shin; Netzahualcóyotl Arroyo-Currás; Gabriel Ortega; Weiwei Li; Arturo A Keller; Kevin W Plaxco; Tod E Kippin
Journal:  Front Mol Biosci       Date:  2019-08-16
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.